Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial
about
Risk factors for disease progression in HER2-positive breast cancer patients based on the location of metastases.Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.Targeted Treatment of Brain Metastases.Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
P2860
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Is risk of central nervous sys ...... roup Phase III BIG 02-98 Trial
@en
Is risk of central nervous system
@nl
type
label
Is risk of central nervous sys ...... roup Phase III BIG 02-98 Trial
@en
Is risk of central nervous system
@nl
prefLabel
Is risk of central nervous sys ...... roup Phase III BIG 02-98 Trial
@en
Is risk of central nervous system
@nl
P2093
P2860
P356
P1433
P1476
Is risk of central nervous sys ...... roup Phase III BIG 02-98 Trial
@en
P2093
B C Pestalozzi
B Nordenskjöld
BIG 02-98 Collaborative Group
E Azambuja
J Gutierrez
J P A Crown
P2860
P304
P356
10.1093/ANNONC/MDN385
P577
2008-06-18T00:00:00Z